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COMMENTARY PAP E R O F TH E MONTH
The search for early markers of AD: hippocampal atrophy and
memory deﬁcits
There is increasing interest in finding markers of
Alzheimer’s disease (AD) that are discriminative
even at an early, pre-dementia stage. This interest
is driven partly by a desire to improve clinical
diagnosis in more mildly affected individuals, and
also by the recent paradigm shift in thinking about
clinical trials for AD. This shift is a result of
concern that the recent failures of high-profile
clinical trials conducted in patients with mild to
moderate AD may have been because therapy
was “too little, too late.” The implication being
that if only treatments had been trialled earlier
they would have had a greater chance of success.
Certainly, lessons from other aspects of medicine
have shown that treatments may be most, or in
some cases only, effective if given early in disease.
If we did have therapies that could slow disease
progression at a very early stage that would increase
the interest in early markers of disease. Ideally, such
therapies would be given when the minimum of
functional decline and irreversible neuronal loss had
already occurred. From economic and public health
standpoints, delaying symptom onset would be very
important: a delay of five years has been estimated
to reduce projections for prevalence of symptomatic
AD by about 50% (Brookmeyer et al., 1998).
We now know there is a long prodromal period
to AD when pathology (amyloid plaques and
neurofibrillary tangles) gradually and progressively
accumulates in the brain. While the exact timing
and sequencing of the different pathological
changes that occur remains to be determined
precisely, evidence from a variety of sources suggests
that cerebral plaques and tangles appear many years
before symptoms. Positron emission tomography
(PET) imaging and cerebrospinal fluid (CSF) stud-
ies have provided in vivo evidence to back up earlier
findings from autopsy studies and collectively these
imply that pathological changes are present and
detectable as early as 10–15 years before symptoms.
Some years after these changes first appear, but
still prior to symptoms, the downstream structural
and functional consequences become apparent. In
particular, longitudinal imaging studies have shown
that pathologically increased hippocampal atrophy
is detectable three to five years before diagnosis.
These findings have led to a reframing of AD
research criteria so that a diagnosis of AD no longer
requires dementia to already be present. The new
criteria state that if supportive biomarker or imaging
changes are present then a diagnosis of prodromal
AD can be made (Dubois et al., 2010; Albert
et al., 2011). Hippocampal atrophy on structural
imaging (MRI (magnetic resonance imaging) or CT
(computed tomography)) is one of the supportive
imaging features included in both these sets of
research criteria.
In this month’s issue of International Psychogeriat-
rics, Ferrarini and colleagues describe the results of
a population-based study of hippocampal volume
and shape abnormalities in elderly subjects with
memory deficits (Ferrarini et al., 2014). Although
a large number of studies have demonstrated
that hippocampal atrophy is associated with AD
and in those with memory deficits is predictive
of future cognitive decline, these have largely
been using highly selected clinical cohorts and
community-based studies are fewer in number.
This is important because the vast majority of
those who are given a clinical diagnosis of AD
are not seen at tertiary referral or AD research
centers. Furthermore, the wider population will
often have multiple co-morbidities which maymean
they are excluded from selective studies. Ferrarini
and colleagues sought to address this issue and
additionally to assess and see changes in the shape
of the hippocampus as well as hippocampal volume
loss. The cohort used in the paper is relevant to
the general population at risk of late-onset AD in
many ways; it is multi-center (from 12 different
rural and urban municipalities) and subjects were
recruited from an epidemiological study rather than
clinics and the age range was from 65 to 84 years.
In this cross-sectional study, the authors compared
three different groups. There were 75 “cognitively
normal” subjects, 31 subjects who had memory
deficits that were felt to be consistent with early AD,
and 31 subjects who had memory deficits but either
did not have a history suggestive of a gradual decline
in memory or who had medical of psychiatric co-
morbidities that presumably were considered as
potential confounds.
So what did they find? Both the memory-
impaired groups had lower hippocampal volumes
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than the control group by about 7% to 8%
and, when considering all the subjects as one
group, lower memory scores were correlated
with lower hippocampal volume. This is indeed
consistent with previous studies and suggests
that these very mildly affected subjects do have
pathological hippocampal losses. Hippocampal
volumes discriminated individuals with memory
deficits from healthy controls with an accuracy of
about 0.6 to 0.7 (area under the receiver operating
characteristic curve). The authors did not find
that their measures of hippocampal shape were
particularly useful in differentiating the different
groups. This may be because, for methodological
reasons, the shape measures were insensitive to
focal losses or alternatively it may suggest that
very early structural changes in AD are rather
diffusely distributed across the hippocampus. A
strength of this study is the fact that the subjects
were drawn from a representative sample of the
general elderly Italian population. So, as the authors
state, the results provide support for the “validity of
hippocampal volumetry as a biomarker of memory
impairment in the general population”. What the
study cannot yet tell us is what the value of
hippocampal volumetry is in terms of early diagnosis
of AD in this population. Importantly however,
the project is ongoing and the authors report that
clinical follow-up is being collected from all the
subjects. Results from this follow-up will make these
baseline data muchmore valuable. At the individual
patient level, it is not whether or not a marker,
be it an imaging measure such as hippocampal
atrophy, or a CSF, or blood biomarker, is associated
with memory deficits but rather whether or not the
marker predicts future clinical decline and can guide
management. Almost 30 years on since Ball and
colleagues suggested that AD should be defined
as a hippocampal dementia, we are still working
out how best (and when) hippocampal measures
can be used to improve early diagnosis (Ball et al.,
1985). This paper shows both the potential and
some of the cautions that need to be associated
with the use of hippocampal measures in very early
disease.
The fact that we are entering a new era of
therapeutic trials in presymptomatic subjects will
add greater urgency to our search for effective
markers of disease and disease progression at
this early stage. These trials will incorporate the
increasing range of markers available: molecular
imaging and CSF fluid biomarkers as well
as hippocampal atrophy. These markers are
currently trying to find their appropriate place in
clinical practice. If an effective disease modifying
therapy is found, that practice is likely to be
transformed.
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